Sharana Mahomed

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial”.

Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial

The Lancet HIV(2023)10.1016/s2352-3018(23)00003-6

N/A

1.1DataRank · unranked

40 citations

Nigel Garrett, Edmund V. Capparelli, Farzana Osman, Nonhlanhla N. Mkhize, Ishana Harkoo +16 more

Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention

The Journal of Infectious Diseases(2022)10.1093/infdis/jiac041

N/A

0DataRank · unranked

36 citations

Nigel Garrett, Edmund V. Capparelli, Farzana Osman, Ishana Harkoo, Nonhlanhla Yende‐Zuma +17 more